<DOC>
	<DOCNO>NCT01576666</DOCNO>
	<brief_summary>The purpose study determine maximum dose LDE225 BKM120 safely give together patient and/or dose use future study . This study also learn combination two investigational drug may work patient certain cancer ( specifically metastatic breast cancer , advance pancreatic adenocarcinoma , metastatic colorectal cancer recurrent glioblastoma multiforme ) .</brief_summary>
	<brief_title>Phase Ib , Dose Escalation Study Oral LDE225 Combination With BKM120 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The primary purpose study determine combination maximum tolerate dose ( MTD ) and/or recommend dose expansion ( RDE ) LDE225 BKM120 co-administered orally patient advance solid tumor . Adult patient , age &gt; 18 year advance solid tumor progress despite standard therapy standard therapy exist eligible study . In dose escalation part study , four group patient follow tumor type enrol : recurrent GBM , metastatic breast cancer , metastatic CRC advance pancreatic adenocarcinoma . It anticipate approximately 45 patient enrol dose escalation part . Approximately 15 GBM patient ( maximum 2 patient per dose level ) enrol previously well-tolerated dos dose escalation slot available cohort active testing . In dose expansion part study , five group patient ( approximately 15 patient per group ) follow tumor type enrol : recurrent GBM , triple negative metastatic breast cancer , hormone receptor positive ( ER+/PR+ , Her2- ) metastatic breast cancer , gastric/gastroesophageal junction cancer , combine maximum 15 patient metastatic CRC advance pancreatic adenocarcinoma . The dose expansion enroll approximately 75 patient . Accounting patient may withdraw may meet eligibility criterion , expect study enroll approximately 120 patient . This multi-center , open-label , dose finding , phase Ib study determine MTD and/or RDE combination LDE225 plus BKM120 , follow expansion part ass safety preliminary efficacy combination patient advance solid tumor frequently associate dysregulated Hh and/or PI3K pathway , specifically triple negative metastatic breast cancer , hormone receptor positive ( ER+/PR+ , Her2- ) metastatic breast cancer , advance pancreatic adenocarcinoma , metastatic CRC , recurrent GBM gastric/gastroesophageal junction cancer patient . Patients treat daily 28-day cycle . Dose escalation dependent available toxicity information ( include adverse event DLTs ) , PK , PD , efficacy information , well recommendation Bayesian Logistic Regression Model ( BLRM ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Male female adult patient ( &gt; 18 year ) 2 . Patients histologically/cytologically confirm diagnosis follow advanced tumor progress despite standard therapy available establish treatment : metastatic breast cancer , pancreatic adenocarcinoma , metastatic CRC recurrent GBM include . 3 . Provision archival tumor sample Novartis designate laboratory molecular profiling . The tumor material submit analysis may obtain time course patient 's disease . 4 . Measurable disease assess RECIST 1.1 nonGBM tumor RANO criterion GBM . 5 . ECOG ( WHO ) performance status 02 6 . Adequate bone marrow organ function 7 . Patient able swallow retain oral medication 8 . Negative serum pregnancy test ; nonlactating postmenopausal woman . 1.Use investigational drug within 30 day enrollment 5 halflives enrollment , whichever longer . 2.History hypersensitivity LDE225 , BKM120 drug similar chemical class . 3.Patient receive previous treatment PI3K inhibitor and/or smoothen inhibitor . 4.Patients recurrent GBM receive radiotherapy within 3 month initiate study treatment . 5.Patients primary CNS tumor ( except recurrent GBM ) , uncontrolled symptomatic CNS metastasis . However , patient control , asymptomatic resect CNS metastasis radiological evidence disease stable brain metastasis progression may eligible . 6.Patients neuromuscular disorder concomitant treatment drug recognize cause rhabdomyolysis , HMG CoA inhibitor ( statin ) , clofibrate gemfibrozil . If essential patient remain statin control hyperlipidemia , Pravastatin may use extra caution . 7.Patients require use warfarin ( substrate CYP2C9 ) enrol LDE225 BKM120 competitive inhibitor CYP2C9 base invitro data . 8.Patient currently treat drug know strong inhibitor inducer CYP3A4/5 , discontinue switched different medication 7 day prior start study treatment duration study . 9.Patient score ≥12 PHQ9 questionnaire . A normal evaluation psychiatrist psychologist overrule exclusion ) . 10.Patients select response `` 1 '' , `` 2 '' `` 3 '' question number 9 PHQ9 questionnaire regard potential suicidal thought ideation ( independent total score PHQ9 ) , ( normal evaluation psychiatrist psychologist overrule exclusion ) . 11.Patient GAD7 mood scale score ≥ 15 , ( normal evaluation psychiatrist psychologist overrule exclusion ) 12.Patient documented medical history active major depression episode , bipolar disorder ( I II ) , obsessive compulsive disorder , schizophrenia , history suicidal attempt ideation , homicidal ideation ( e.g . risk harm self others ) 13 . Patient ≥CTCAE grade 3 anxiety 14.Current medical history following : Use pacemaker History presence clinically significant ventricular atrial tachyarrhythmia Clinically significant rest bradycardia ( &lt; 45 beat per minute ) History clinically document myocardial infarction History unstable angina pectoris History know structural abnormality ( i.e . cardiomyopathy ) 15.Clinically significant cardiovascular disease 16.Clinically significant abnormal ECG 17.Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % determined Multiple Gated Acquisition ( MUGA ) scan echocardiogram ( ECHO ) 18.Patient currently receive treatment QT prolong medication know risk induce Torsades de Pointes , treatment discontinue switched different medication 7 day prior start study duration study 19.Patients willing apply highly effective contraception define protocol study duration study . Note : Hormonal contraception method ( e.g . oral , injected , implant ) allow rule study drug decrease effectiveness hormonal contraception 20.Sexually active male unwilling use condom intercourse take drug 6 month stop investigational medication agree father child period . 21.Patients currently receive increase chronic treatment corticosteroid ( ( ≥ antiinflammatory potency 4mg dexamethasone ) another immunosuppressive agent . 22.Patient treat hematopoietic colonystimulating growth factor ( e.g. , GCSF , GMCSF ) ≤ 2 week prior start study drug . Erythropoietin darbepoetin therapy , initiate enrollment , may continue 23.Patient received chemotherapy , target therapy immunotherapy ≤ 3 week ( 6 week nitrosourea , mitomycinC monoclonal antibody ; 1 week hormonal anticancer therapy ) prior start study drug recover grade 1 well related side effect therapy ( exception include alopecia , bone marrow organ function ) 24.Patient impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption LDE225 BKM120 ( e.g. , ulcerative colitis , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) 25.Patient know history HIV infection ( test mandatory ) AMENDMENT 1 CHANGES : 3 . Provision archival tumor sample Novartis designate laboratory molecular profiling . It accept may possible obtain sample prior commence study treatment . It also accept may possible obtain sample ( e.g . sufficient sample exist ) , situation inclusion patient discuss Novartis ( may make patient ineligible ) . 5 . Patients primary CNS tumor ( except recurrent GBM ) , uncontrolled symptomatic CNS metastasis . However , patient control , asymptomatic resect CNS metastasis radiological evidence disease stable brain metastasis progression may eligible . The patient must complete prior treatment CNS metastasis ( include radiotherapy and/or surgery ) ≥ 28 day ( &gt; 14 day stereotactic radiosurgery ) . 9 . Patient score ≥12 PHQ9 questionnaire . A normal evaluation psychiatrist overrule exclusion . 10.Patients select response `` 1 '' , `` 2 '' `` 3 '' question number 9 PHQ9 questionnaire regard potential suicidal thought ideation ( independent total score PHQ9 ) , ( normal evaluation psychiatrist overrule exclusion ) . 11.Patient GAD7 mood scale score ≥ 15 , ( normal evaluation psychiatrist overrule exclusion ) AMENDMENT 2 CHANGES : Updated 3 . Revised specify group patient include dose escalation dose expansion part ( NEW tumor type add ) : Patients histologically/cytologically confirm diagnosis follow advanced tumor progress despite standard therapy available establish treatment : four group patient dose escalation part : metastatic breast cancer , advance pancreatic adenocarcinoma , metastatic CRC recurrent GBM five group dose expansion part : triple negative metastatic breast cancer , hormone receptor positive ( ER+/PR+ , Her2 ) metastatic breast cancer , recurrent GBM , GASTRIC/GASTROESOPHAGEAL JUNCTION CANCER , advance pancreatic adenocarcinoma metastatic CRC include . 6 . ECOG ( WHO ) performance status 02 . ADDED `` apply patient enrol original Amendment 1 protocol version . '' 7 . Two subbullets update : Potassium , calcium , within normal limit institution . Out range value clinically insignificant . Serum Creatinine ≤ 1.5 x ULN 24hour creatinine clearance ≥ 50 mL/min ( determined inputting serum creatinine result CockcroftGault formula ) . 9 . NEW Inclusion criterion : Recurrent GBM patient Karnofsky performance status ( KPS ) score ≥ 70 . 10 . NEW Inclusion criterion : ECOG ( WHO ) performance status 01 ( applies patient enrol Amendment 2 later protocol version ) . Updated 12 . Patient score ≥12 PHQ9 questionnaire . REMOVED `` A normal evaluation psychiatrist overrule exclusion . '' 13.Patients select response `` 1 '' , `` 2 '' `` 3 '' question number 9 PHQ9 questionnaire regard potential suicidal thought ideation ( independent total score PHQ9 ) . REMOVED `` A normal evaluation psychiatrist overrule exclusion . '' 14 . Patient GAD7 mood scale score ≥ 15 . REMOVED `` A normal evaluation psychiatrist overrule exclusion . '' 15 . Patient document medical history active major depression episode , bipolar disorder ( I II ) , obsessive compulsive disorder , schizophrenia , history suicidal attempt ideation . ADDED `` homicidal ideation ( e.g . risk harm self others ) , patient active severe personality disorder ( define accord DSM IV , Diagnostic Statistical Manual Mental Disorders , 4th edition ) eligible . Note : patient psychotropic treatment ongoing baseline , dose schedule modify within previous 6 week prior start study drug . '' 23 . REMOVED mention `` Double barrier method '' term `` Male patient '' section 27 . Patient receive chemotherapy , target therapy immunotherapy ≤ 3 week ( 6 week nitrosourea , mitomycinC ; 6 week monoclonal antibody carryover effect suspect ; 1 week hormonal anticancer therapy ) prior start study drug recover grade 1 well related side effect therapy ( exception include alopecia , bone marrow organ function ) . ADDED clarification concern washout period monoclonal antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Dose escalation</keyword>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>MTD</keyword>
	<keyword>Safety Expansion</keyword>
	<keyword>Safety</keyword>
	<keyword>Preliminary Efficacy</keyword>
	<keyword>Objective Response Rate</keyword>
	<keyword>Early progression rate</keyword>
	<keyword>PI3K activation</keyword>
	<keyword>Combination Treatment</keyword>
	<keyword>Hedgehog Signaling Pathway</keyword>
	<keyword>Smoothened inhibitor</keyword>
	<keyword>Phosphoinositide-3 ' kinase</keyword>
	<keyword>Phosphatase signal pathway</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>advanced pancreatic adenocarcinoma</keyword>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>recurrent glioblastoma multiforme</keyword>
	<keyword>gastric cancer</keyword>
	<keyword>gastroesophageal junction cancer</keyword>
	<keyword>triple negative metastatic breast cancer</keyword>
	<keyword>hormone receptor positive ( ER+/PR+ , Her2- ) metastatic breast cancer</keyword>
</DOC>